Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Treatment of AD/HD HasReached a Stalemate: Prof. Tanaka
April 6, 2009
- 1st Seminar to Promote Use of Generics Held
April 6, 2009
- JSHP Concerned about Exposure of Pharmacists to Anticancer Drugs
April 6, 2009
- Korosho's Survey Confirms Low Generic Substitution Rate
April 6, 2009
- Increases in People's Financial Burden Are Inevitable: MOF
April 6, 2009
- 78.6% of Pharmacies Obtain Premium for Dispensing Generics
April 6, 2009
- Awareness Rate for CKD only 10%: Healthclick
April 6, 2009
- Studies Voluntarily Conducted by Physicians Must Be Funded by Contracts
March 30, 2009
- Takara Bio Supplies RetroNectin for 46th Clinical Trial
March 30, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 30, 2009
- JAPhMed to Be Incorporated into Medical Society in April
March 30, 2009
- Takara Bio Licenses LA-PCR Methods to Biotools of Spain
March 30, 2009
- LDP Diet Members Not Persuaded about Safety of Online Sale
March 30, 2009
- Tanaka Kikinzoku Develops Flu Virus Detection Reagent Using Gold Particles
March 30, 2009
- Mr Ishii of JPA Rages at Mr Mikitani
March 30, 2009
- Asubio Pharma to Specialize in Drug Discovery
March 30, 2009
- RDKK to Enhance Focus on Prediction of Efficacy of Anticancer Drugs
March 30, 2009
- BUSINESS NEWS IN BRIEF
March 30, 2009
- Drugs Eligible for Price Maintenance Must Be Strictly Selected: Chuikyo
March 30, 2009
- FPMAJ Should Maintain Its Stance Regarding Range of Drugs Eligible for Price Maintenance System: Mr Nagano
March 30, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…